Covid-19 roundup: Mer­ck shares mol­nupi­ravir with a UN-backed non­prof­it; GSK halts Covid-19 re­search on mon­o­clon­al an­ti­body

Mer­ck has agreed to li­cense mol­nupi­ravir to UN-backed non­prof­it Med­i­cines Patent Pool.

The non­prof­it will be work­ing with mul­ti­ple drug­mak­ers to pro­duce mol­nupi­ravir for 105 na­tions, in­clud­ing Pak­istan, Cam­bo­dia and all of Africa, the com­pa­ny and non­prof­it said Wednes­day.

Al­though MPP said it’s still un­clear how many pills will be pro­duced un­der the li­cens­ing deal —once man­u­fac­tur­ers’ plants are ful­ly op­er­a­tional, the non­prof­it pre­dict­ed that some man­u­fac­tur­ers will be able to start de­liv­er­ies this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER